177 related articles for article (PubMed ID: 9749583)
21. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.
Rosenblad C; Martinez-Serrano A; Björklund A
Neuroscience; 1998 Jan; 82(1):129-37. PubMed ID: 9483509
[TBL] [Abstract][Full Text] [Related]
22. Functional recovery in parkinsonian monkeys treated with GDNF.
Gash DM; Zhang Z; Ovadia A; Cass WA; Yi A; Simmerman L; Russell D; Martin D; Lapchak PA; Collins F; Hoffer BJ; Gerhardt GA
Nature; 1996 Mar; 380(6571):252-5. PubMed ID: 8637574
[TBL] [Abstract][Full Text] [Related]
23. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D
Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.
Georgievska B; Kirik D; Rosenblad C; Lundberg C; Björklund A
Neuroreport; 2002 Jan; 13(1):75-82. PubMed ID: 11924898
[TBL] [Abstract][Full Text] [Related]
25. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration.
Palfi S; Leventhal L; Chu Y; Ma SY; Emborg M; Bakay R; Déglon N; Hantraye P; Aebischer P; Kordower JH
J Neurosci; 2002 Jun; 22(12):4942-54. PubMed ID: 12077191
[TBL] [Abstract][Full Text] [Related]
26. Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum.
Kobayashi S; Ogren SO; Hoffer BJ; Olson L
Exp Neurol; 1998 Dec; 154(2):302-14. PubMed ID: 9878169
[TBL] [Abstract][Full Text] [Related]
27. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys.
Zhang Z; Miyoshi Y; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1396-401. PubMed ID: 9316852
[TBL] [Abstract][Full Text] [Related]
28. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease.
Winkler C; Sauer H; Lee CS; Björklund A
J Neurosci; 1996 Nov; 16(22):7206-15. PubMed ID: 8929429
[TBL] [Abstract][Full Text] [Related]
29. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons.
Horger BA; Nishimura MC; Armanini MP; Wang LC; Poulsen KT; Rosenblad C; Kirik D; Moffat B; Simmons L; Johnson E; Milbrandt J; Rosenthal A; Bjorklund A; Vandlen RA; Hynes MA; Phillips HS
J Neurosci; 1998 Jul; 18(13):4929-37. PubMed ID: 9634558
[TBL] [Abstract][Full Text] [Related]
30. Trophic factor distribution predicts functional recovery in parkinsonian monkeys.
Gash DM; Zhang Z; Ai Y; Grondin R; Coffey R; Gerhardt GA
Ann Neurol; 2005 Aug; 58(2):224-33. PubMed ID: 16049934
[TBL] [Abstract][Full Text] [Related]
31. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo.
Tomac A; Lindqvist E; Lin LF; Ogren SO; Young D; Hoffer BJ; Olson L
Nature; 1995 Jan; 373(6512):335-9. PubMed ID: 7830766
[TBL] [Abstract][Full Text] [Related]
32. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
33. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
Iravani MM; Costa S; Jackson MJ; Tel BC; Cannizzaro C; Pearce RK; Jenner P
Eur J Neurosci; 2001 Feb; 13(3):597-608. PubMed ID: 11168568
[TBL] [Abstract][Full Text] [Related]
34. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.
Choi-Lundberg DL; Lin Q; Schallert T; Crippens D; Davidson BL; Chang YN; Chiang YL; Qian J; Bardwaj L; Bohn MC
Exp Neurol; 1998 Dec; 154(2):261-75. PubMed ID: 9878166
[TBL] [Abstract][Full Text] [Related]
35. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages.
Aoi M; Date I; Tomita S; Ohmoto T
Neurosci Res; 2000 Apr; 36(4):319-25. PubMed ID: 10771110
[TBL] [Abstract][Full Text] [Related]
36. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo.
Sullivan AM; Opacka-Juffry J; Blunt SB
Eur J Neurosci; 1998 Jan; 10(1):57-63. PubMed ID: 9753113
[TBL] [Abstract][Full Text] [Related]
37. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats.
Bowenkamp KE; Lapchak PA; Hoffer BJ; Miller PJ; Bickford PC
Exp Neurol; 1997 May; 145(1):104-17. PubMed ID: 9184114
[TBL] [Abstract][Full Text] [Related]
38. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
Lapchak PA; Araujo DM; Hilt DC; Sheng J; Jiao S
Brain Res; 1997 Nov; 777(1-2):153-60. PubMed ID: 9449424
[TBL] [Abstract][Full Text] [Related]
39. GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats.
Wang Y; Tien LT; Lapchak PA; Hoffer BJ
Cell Tissue Res; 1996 Nov; 286(2):225-33. PubMed ID: 8854891
[TBL] [Abstract][Full Text] [Related]
40. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
Kirik D; Georgievska B; Rosenblad C; Björklund A
Eur J Neurosci; 2001 Apr; 13(8):1589-99. PubMed ID: 11328352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
